Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 19 years old or above~2. Patients who confirmed essential hypertension with Hyperlipidemia or use of drugs at Visit 1 (sit systolic blood pressure ≥ 140mmHg, LDL-Cholesterol ≥ 100mg/dL)~3. Patients who can stop the treatment of anti-hypertensive/anti-hyperlipidemic drugs in the opinion of the investigator~4. Test results showing the following values at screening time (Visit 2) : sit systolic blood pressure \>140mmHg~5. Test results showing the following values at screening time (Visit 2) : 100\< LDL-Cholesterol \<250~6. Patients who agreed to participate in the trial~Exclusion Criteria:~1. Severe hypertension patients(systolic blood pressure ≥ 180 mm Hg or diastolic blood pressure ≥ 110 mm Hg)~   -The change of mean sit systolic blood pressure ≥ 20 mmHg or sit diastolic blood pressure ≥ 10 mmHg on target arm between 1st and 2nd measurement~2. LDL-Cholesterol \> 250 mg/dL or triacylglycerol ≥ 400 mg/dL at screening time(Visit 1)~3. Patients with postural hypotension who have sign and symptom~4. Patients with secondary blood pressure(for example,aortic coarctation, hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, Polycystic Kidney Diseases)~5. Patients with congestive heart failure(New York Heart Association class III\~IV)~6. Patients with history of acute coronary syndrome or underwent revascularization (percutaneous transluminal coronary angioplasty or Coronary Artery Bypass Graft surgery ) within 6 months~7. Patients who have severe ventricular tachycardia, atrial fibrillation, atrial flutter or clinically significant arrhythmia~8. Causes of hemodynamic disorder or structural heart defect such as valvular heart disease~9. Patients who have history of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months prior to study entry~10. Patients with primary aldosteronism~11. Patients with severe ocular disorders~12. Patients with autoimmune disease~13. Patients with any chronic inflammation disease needed to chronic inflammation therapy~14. Patients with uncontrolled diabetes Mellitus with HbA1c \> 9% or thyroid diseases(TSH ≥ 1.5 X ULN)~15. Patients who have a history of myopathy or rhabdomyolysis~16. Patients who have 3 times of upper limit of normal range of muscle enzyme (creatinine kinase, CK)~17. History of malignant tumor including leukemia, lymphoma within 5 years~18. Patients with one kidney~19. Patients with biliary obstructive disorder~20. Patients with clinically significant electrolyte disturbance~21. Continued serum potassium concentration abnormal status (\<3.5mEq/L or \>5.5mEq/L)~22. Patients with sodium ion or body fluid is depleted and not able to correct~23. Patients with clinically significant liver/renal disease~24. Patients with digestive diseases that may affect the absorption or history in gastrointestinal surgery~25. Patients who are dependent on drugs or alcohol~26. Pregnancy, breast-feeding, or child-bearing potential Patients~27. Patients with hypersensitivity to telmisartan or other angiotensin II receptor blockers~28. Patients with hypersensitivity to Amlodipine or other dihydropyridine drugs~29. Patients with history of Myotoxicity to other 3-hydroxy-methyl glutaryl-coenzyme A reductase inhibitor or fibrate~30. Patients who are unable to stop taking prohibited drugs to combination during study period~31. Patients who have galactose intolerance~32. Patients taking other clinical trial drugs within 30 days from the time of visit for screening~33. Patients that is not eligible to participate at the discretion of study investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telmisartan/Amlodipine+Rosuvastatin (Type: EXPERIMENTAL): Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.
- Telmisartan/Amlodipine (Type: ACTIVE_COMPARATOR): Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.
- Telmisartan +Rosuvastatin (Type: ACTIVE_COMPARATOR): Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete